Brincidofovir
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ebola Virus Disease
Conditions
Ebola Virus Disease
Trial Timeline
Oct 1, 2014 → Dec 1, 2015
NCT ID
NCT04268966About Brincidofovir
Brincidofovir is a phase 2 stage product being developed by Jazz Pharmaceuticals for Ebola Virus Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04268966. Target conditions include Ebola Virus Disease.
What happened to similar drugs?
2 of 4 similar drugs in Ebola Virus Disease were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02596997 | Pre-clinical | Completed |
| NCT03339401 | Phase 2 | Terminated |
| NCT02420080 | Pre-clinical | Terminated |
| NCT04268966 | Phase 2 | Withdrawn |
| NCT02087306 | Phase 3 | Completed |
| NCT01769170 | Phase 3 | Completed |
| NCT01143181 | Phase 3 | Completed |
| NCT01241344 | Phase 2 | Completed |
Competing Products
20 competing products in Ebola Virus Disease